Does USTEKINUMAB Cause Inappropriate schedule of product administration? 2,166 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 2,166 reports of Inappropriate schedule of product administration have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 2.5% of all adverse event reports for USTEKINUMAB.
2,166
Reports of Inappropriate schedule of product administration with USTEKINUMAB
2.5%
of all USTEKINUMAB reports
42
Deaths
256
Hospitalizations
How Dangerous Is Inappropriate schedule of product administration From USTEKINUMAB?
Of the 2,166 reports, 42 (1.9%) resulted in death, 256 (11.8%) required hospitalization, and 49 (2.3%) were considered life-threatening.
Is Inappropriate schedule of product administration Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 2,166 reports have been filed with the FAERS database.
What Other Side Effects Does USTEKINUMAB Cause?
Drug ineffective (12,471)
Off label use (10,990)
Product dose omission issue (9,405)
Fatigue (5,457)
Product use issue (5,008)
Psoriasis (4,955)
Pain (4,872)
Rash (4,736)
Crohn's disease (4,662)
Arthralgia (4,608)
What Other Drugs Cause Inappropriate schedule of product administration?
ADAPALENE (16,473)
DUPILUMAB (14,927)
AVOBENZONE\OCTISALATE\OCTOCRYLENE (12,546)
INSULIN GLARGINE (8,982)
INFLIXIMAB (6,847)
INFLIXIMAB-DYYB (5,977)
SECUKINUMAB (4,817)
DULAGLUTIDE (3,606)
VEDOLIZUMAB (3,259)
SACUBITRIL\VALSARTAN (2,870)
Which USTEKINUMAB Alternatives Have Lower Inappropriate schedule of product administration Risk?
USTEKINUMAB vs USTEKINUMAB-STBA
USTEKINUMAB vs VADADUSTAT
USTEKINUMAB vs VALACYCLOVIR
USTEKINUMAB vs VALBENAZINE
USTEKINUMAB vs VALBENAZINE DITOSYLATE